The Women's Cardiac Screening Lab Panel: What to Order at 45 and How to Ask

A 45-year-old woman presenting for an annual physical typically leaves with results from a complete blood count, comprehensive metabolic panel, TSH, and standard lipid panel. She is told her results are normal. She accepts this as a clean cardiovascular bill of health.

What the panel she received cannot tell her:

Whether her ApoB is elevated (atherogenic particle burden invisible on standard lipid panels). Whether she carries elevated Lp(a) (the genetic risk factor present in 1 in 5 women and never measured by default). Whether her fasting insulin is elevated (insulin resistance that begins years before any change in fasting glucose). Whether she has low-grade systemic inflammation driving vascular risk. Whether her iron stores are depleted, causing the fatigue and palpitations she has been attributing to stress.

This guide covers what a cardiologist would add to the standard 45-year-old panel, in clinical priority order, with the exact language to use when requesting each test.

The standard panel: what it covers and what it does not

The standard panel was designed for efficiency and broad-based screening. For detecting acute illness, monitoring chronic disease, and flagging frank metabolic derangement, it works. For detecting the cardiovascular risk trajectory of a perimenopausal woman 10-15 years before her first cardiac event, it is insufficient.

What it detects well: overt anemia, thyroid dysfunction, kidney disease, frank diabetes, dramatically elevated LDL.

What it misses: insulin resistance (fasting glucose is normal while compensatory hyperinsulinemia is already underway), atherogenic particle burden in women with small-dense LDL predominance, genetic lipid risk factors, vascular inflammation, iron deficiency without anemia.

ApoB: the particle count

What it is: ApolipoproteinB-100 is a structural protein present on every atherogenic lipoprotein particle. VLDL, IDL, LDL, Lp(a). One ApoB per particle. ApoB is therefore a direct count of atherogenic particles. LDL-C tells you how much cholesterol is in the particles; ApoB tells you how many particles there are.

Why it matters for women at 45: In the perimenopause transition, hormonal changes shift lipoprotein composition toward smaller, denser LDL particles. These particles are more atherogenic per unit of cholesterol content and appear as lower LDL-C on standard testing, while ApoB remains elevated. A woman with LDL 95 mg/dL and ApoB 130 mg/dL has substantially more atherogenic burden than her LDL report suggests. 5 / Solid

Target: Below 90 mg/dL for most women. Below 70 mg/dL if established cardiovascular disease, diabetes, or PCOS with metabolic features is present.

How to request: “I’d like to add ApoB to my standard lipid panel, it’s recommended as a secondary risk marker in the ACC/AHA guidelines when LDL may not fully reflect cardiovascular risk.”

Lp(a): the genetic risk factor

What it is: Lipoprotein(a) is a modified LDL-like particle with an additional apo(a) protein attached. It is more inflammatory, more thrombogenic, and more adhesive to arterial walls than standard LDL. Unlike other lipid risk factors, it is almost entirely genetically determined and does not respond meaningfully to diet or lifestyle. 5 / Solid

Why it matters for women at 45: Approximately 20% of women carry elevated Lp(a) (above 50 mg/dL or 125 nmol/L). In Black women, prevalence and average levels are higher. Women who had SCAD, unexplained MI under 55, or a sibling who had premature coronary disease may have elevated Lp(a) as an underrecognized driver.

Timing: Order once. Lp(a) is genetically determined and stable across a lifetime. One test, documented in the permanent medical record, establishes the baseline.

How to request: “Has my Lp(a) been measured? The ACC and ESC both recommend Lp(a) screening at least once in every adult, and it has never been ordered in my chart.”

hs-CRP: vascular inflammation

What it is: High-sensitivity CRP measures the same C-reactive protein as standard CRP but at low concentrations calibrated for cardiovascular risk assessment at baseline. Standard CRP detects acute illness; hs-CRP detects the chronic low-grade inflammation that drives atherosclerosis progression.

Why it matters for women at 45: The JUPITER trial demonstrated that rosuvastatin significantly reduced cardiovascular events in patients with elevated hs-CRP and normal LDL, a population that standard lipid panel assessment would classify as low-risk. Women have higher baseline hs-CRP than men due to hormonal cycling, which means the threshold for cardiovascular relevance needs sex-specific context. hs-CRP above 2.0 mg/L in a woman with otherwise unremarkable standard labs warrants attention. 5 / Solid

How to request: “I’d like to add hs-CRP, the high-sensitivity version , to assess vascular inflammation as part of my cardiovascular risk picture.”

Fasting insulin: the early insulin resistance signal

What it is: Fasting insulin measures the amount of insulin the pancreas is producing after a period of fasting. In insulin resistance, the pancreas compensates by producing more insulin to achieve the same glucose-lowering effect. Fasting glucose appears normal while fasting insulin is elevated, the glucose is normal because the pancreas is working harder.

Why it matters for women at 45: Insulin resistance begins silently, often years or decades before A1c or fasting glucose become abnormal. In the perimenopause transition, insulin sensitivity decreases even in the absence of dietary change, a consequence of declining estrogen’s insulin-sensitizing effects on muscle tissue. A woman with fasting insulin above 10 uIU/mL and normal fasting glucose has established insulin resistance with cardiovascular consequences: elevated blood pressure, visceral adiposity, small-dense LDL, and inflammatory cytokine production. 5 / Solid

How to request: “I’d like fasting insulin added to this year’s labs. I’ve heard it can detect insulin resistance earlier than fasting glucose.”

Ferritin: iron stores

What it is: Ferritin is the storage protein for iron. Low ferritin indicates depleted iron stores. Critically, ferritin can be significantly low, below 30 ng/mL , while hemoglobin remains entirely normal. This is iron deficiency without anemia.

Why it matters for women at 45: Iron deficiency without anemia is the most common micronutrient deficiency in women of reproductive age. Its symptoms, fatigue, palpitations, reduced exercise tolerance, elevated resting heart rate , are identical to several cardiac conditions. When a 44-year-old woman presents with heart rate of 92 at rest, fatigue on exertion, and palpitations at night, the differential includes arrhythmia, early heart failure, and iron deficiency. Ferritin distinguishes these before cardiology evaluation begins.

Additional reason: low ferritin shortens red blood cell lifespan, causing A1c to underestimate average glucose. A woman with iron deficiency cannot rely on A1c as an accurate glucose biomarker.

Target: Ferritin above 50 ng/mL for symptom resolution in women with iron deficiency symptoms.

How to request: “Can we add ferritin to this panel? I’ve been having fatigue and palpitations and want to rule out iron deficiency without anemia.”

Vitamin D (25-OH): cardiovascular relevance

What it is: 25-hydroxyvitamin D is the storage form measured by blood test. Deficiency is defined as below 20 ng/mL; insufficiency as 20-29 ng/mL.

Why it matters for women at 45: Vitamin D deficiency is associated with higher blood pressure, higher inflammatory marker levels, and higher cardiovascular event rates in observational studies. Whether vitamin D supplementation specifically reduces cardiovascular events is not clearly established, but deficiency is common, easy to identify, and correctable. Women with darker skin tone have higher deficiency rates due to reduced cutaneous vitamin D synthesis. 4 / Promising

How to request: Include in annual panel as “vitamin D, 25-OH total.”

DHEA-S: adrenal reserve and sex steroid precursor

What it is: DHEA-S (dehydroepiandrosterone sulfate) is the most abundant circulating sex-steroid precursor, produced by the adrenal glands. It declines substantially after 40 and correlates with fatigue, reduced muscle mass, and insulin resistance. It is not a direct cardiovascular risk marker, but provides clinical context for the hormonal milieu at 45.

How to request: “I’d like DHEA-S checked as part of a baseline hormonal assessment. I’ve been noticing fatigue and reduced exercise tolerance.”

Direct-to-consumer options if tests are declined

If your physician declines these additions, you can order most of them without a physician order through:

• LabCorp Patient Direct (labcorppatientdirect.com)
• Quest Health (questhealth.com)
• Function Health (functionhealth.com), comprehensive panel including all of the above

The cardiovascular-specific panel at most of these services includes ApoB, Lp(a), hs-CRP, fasting insulin, ferritin, vitamin D, and DHEA-S for under $200 total.

The conversation at your next appointment

Three sentences:

“I’d like to add ApoB, fasting insulin, hs-CRP, Lp(a), ferritin, and vitamin D to this year’s labs. These are cardiovascular risk markers recommended beyond the standard panel for women in their 40s.”

“Has Lp(a) ever been measured in my chart? It only needs to be done once and is recommended by the ACC at least once in every adult’s lifetime.”

“Is a coronary artery calcium score appropriate for me? I’d like to understand whether we should add that to my preventive assessment.”

Reading results in combination: why borderline-everything is not the same as clearly normal

A single mildly abnormal result is easy to dismiss. A cluster of borderline results pointing in the same direction is a different clinical picture, and the two situations should not be treated equivalently.

Consider a 45-year-old woman with the following individual results, each of which a standard report might flag as “normal” or “borderline”:

• LDL-C: 108 mg/dL (normal reference range: below 130)
• ApoB: 95 mg/dL (borderline; above 90 but below overt treatment threshold)
• Fasting insulin: 12 uIU/mL (mildly elevated; above 10)
• hs-CRP: 2.4 mg/L (slightly elevated; above the 2.0 mg/L cardiovascular relevance threshold)
• Triglycerides: 138 mg/dL (borderline; below 150 is “normal”)
• Fasting glucose: 96 mg/dL (normal; below 100)

Each value in isolation generates no clinical alarm. Taken together, this pattern — modest atherogenic particle load, early insulin resistance, and low-grade vascular inflammation — is the metabolic fingerprint of early cardiovascular risk, particularly in the context of perimenopause. 5 / Solid

This is the case for ordering the panel as a panel, not as individual tests. The signal lives in the pattern, not in any single number.

The combination that warrants most attention: Elevated ApoB (above 90) + elevated fasting insulin (above 10) + hs-CRP above 2.0 mg/L + triglycerides trending upward — even when every individual marker falls within its labeled “normal” range. This combination reflects the atherogenic triad of metabolic dysfunction that precedes visible coronary disease by 10 to 15 years in women. 5 / Solid

What to do if your results form this pattern: Bring the full panel to your appointment rather than waiting for individual flags. Ask: “Several of these markers are borderline in the same direction. What does that suggest about my overall cardiovascular trajectory, and does it change what we should be monitoring?”

Sex-specific thresholds: where standard reference ranges mislead women

Most laboratory reference ranges were established in predominantly male study populations, or combined populations where male physiology dominates the distribution. For women, several reference ranges require sex-specific interpretation.

hs-CRP in women: Women have naturally higher baseline hs-CRP than men due to menstrual cycling, oral contraceptive use, and estrogen’s effect on hepatic CRP production. This means a woman with hs-CRP of 1.8 mg/L and a man with hs-CRP of 1.8 mg/L are not in equivalent risk positions. For cardiovascular risk stratification, standard thresholds apply — below 1.0 mg/L is low risk, 1.0–3.0 mg/L is moderate risk, above 3.0 mg/L is high risk — but a woman near the upper end of a category deserves more attention than the number alone suggests. Importantly, hs-CRP above 3.0 mg/L in a woman not in the luteal phase of her cycle, not actively ill, and not taking oral contraceptives suggests meaningful vascular inflammation. 5 / Solid

ApoB targets in women: Published ApoB targets were derived largely from mixed-sex statin trials. For primary prevention in women without diabetes or established disease, an ApoB below 90 mg/dL is the standard target. However, women with PCOS, type 2 diabetes, or an Lp(a) above 50 mg/dL should have a more aggressive target of below 70 mg/dL applied, because each of these conditions compounds atherogenic particle burden beyond what ApoB alone captures. 5 / Solid

Hemoglobin A1c in iron-deficient women: A1c measures the percentage of hemoglobin that has accumulated glucose over approximately three months. When iron deficiency shortens red blood cell lifespan, cells are replaced faster, and each new cell has had less time to accumulate glucose. The result: A1c underestimates average glucose in iron-deficient women — sometimes by 0.3–0.5 percentage points. A woman with ferritin below 20 ng/mL and an A1c of 5.3% may have a true glucose picture closer to 5.6–5.8%. This is clinically meaningful near the prediabetes threshold. Ferritin and A1c should always be interpreted together. 5 / Solid

Fasting insulin in perimenopausal women: There is no universally agreed laboratory reference range for fasting insulin; many labs report “normal” up to 20–25 uIU/mL, a range calibrated for populations that include men and younger women with higher estrogen-mediated insulin sensitivity. For a 45-year-old woman in perimenopause, fasting insulin above 10 uIU/mL in the context of any other metabolic signal (borderline triglycerides, visceral fat, rising ApoB) should be considered clinically significant, not simply “within range.” 4 / Promising

Repeat intervals: how often to retest each marker

Not every test needs to be repeated annually. The appropriate repeat interval depends on the initial result and the stability of underlying risk factors.

Lp(a): once in a lifetime. Lp(a) is genetically determined and does not change meaningfully with diet, exercise, or most medications. A single measurement, documented in the permanent medical record, establishes the baseline that informs every future treatment-target decision. No repeat testing is needed unless a specific clinical question arises — for example, calibrating response to an emerging Lp(a)-lowering agent in a clinical trial context.

ApoB: annually if previously elevated; every 2–3 years if normal and stable. ApoB responds to dietary composition, weight change, and lipid-lowering therapy. If ApoB was above 90 mg/dL or if metabolic risk factors (insulin resistance, perimenopausal transition, PCOS) are active, annual testing tracks whether the burden is increasing. If ApoB was clearly below 80 mg/dL with no active metabolic risk factors, a 2–3 year interval is reasonable. 5 / Solid

hs-CRP: annually if previously above 2.0 mg/L; every 2 years if below 1.0 mg/L. Because hs-CRP fluctuates with illness, stress, and hormonal cycling, a single elevated result should be confirmed with a second measurement 2–4 weeks later before acting on it. If both measurements are above 2.0 mg/L, annual monitoring is appropriate. Do not test hs-CRP during active infection, acute illness, or during the luteal phase of the menstrual cycle, as these states transiently elevate the result.

Fasting insulin: annually if previously elevated or metabolic risk factors are present. Insulin resistance is a dynamic state. It worsens with weight gain, sleep disruption, and the estrogen decline of perimenopause, and it improves with targeted lifestyle change. Annual testing captures whether the trajectory is moving in the right direction.

Ferritin: annually until normalized, then every 2 years if stable. Iron stores in menstruating women fluctuate with menstrual blood loss, dietary intake, and supplementation. Until ferritin is consistently above 50 ng/mL, annual monitoring confirms the deficiency has been corrected and maintained. After two consecutive years above 50 ng/mL without active bleeding history, a 2-year interval is reasonable.

Vitamin D (25-OH): annually until above 40 ng/mL and maintained; every 2 years thereafter. Vitamin D status is highly variable with sun exposure and supplementation compliance. Annual testing during supplementation confirms adequacy and avoids under- or over-correction.

DHEA-S: at baseline, then every 2–3 years or when new symptoms suggest adrenal reserve change — persistent fatigue, significant decline in muscle mass, or mood changes inconsistent with thyroid or sleep explanations.

What to do this week

If the panel in this article has not been ordered, the barrier is usually one conversation. Here is how to move from reading this to having the tests in hand.

Step 1: Before your appointment. Write down the specific tests you want: ApoB, Lp(a), hs-CRP (high-sensitivity), fasting insulin, ferritin, vitamin D (25-OH). Note whether Lp(a) has ever appeared in your prior lab work. Most electronic medical record patient portals let you search your past results — if “Lp(a)” or “lipoprotein(a)” does not appear, it has not been ordered.

Step 2: At the appointment. Use this language: “I’d like to request an expanded cardiovascular panel. I’d like ApoB, Lp(a) (if it hasn’t been run), fasting insulin, hs-CRP, ferritin, and vitamin D added. These are markers relevant to my cardiovascular risk profile at this stage and I’m happy to come back fasting if needed.” The fasting requirement applies to fasting insulin and triglycerides; the other tests can be drawn non-fasting.

Step 3: If any tests are declined. Ask the physician to note in the chart that you requested the test. Then order the declined tests through LabCorp Patient Direct, Quest Health, or Function Health. Bring those results to your next appointment. Results you ordered yourself are legitimate clinical data and can be added to your medical record upon request.

Step 4: When your results arrive. Do not accept a summary statement of “everything looks fine” without seeing the actual values. Request a copy of every result with the reference range. Look for the pattern described earlier in this article — borderline-everything in the same direction is not the same as clearly normal.

Step 5: Document what you learn. Lp(a) especially — note it, store it with your medical documents, and mention it any time you see a new provider, change insurers, or are referred to a cardiologist. This single number informs treatment targets for the rest of your life and is almost never spontaneously retrieved from prior records.

Related reading

For what happens when you bring back elevated results: The Five Numbers Every Woman Should Know.

For the ApoB-Lp(a) picture specifically: see the full Five Numbers module discussion.

For why the annual physical misses these tests by default: Your Annual Physical Was Normal. The Female Cardiac Tests They Did Not Run.